Leucocyte and eosinophil counts predict progression‐free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.

The article provides information on a study which observed the link between different blood count parameters at baseline with response and progression-free survival (PFS) in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) patients treated with the anti-PD1 antibody, nivolumab. Topics discussed include role of eosinophils as co-effectors of the immune response, and results of the study.